Meeting Report: WHO Workshop on modelling global mortality and aetiology estimates of enteric pathogens in children under five. Cape Town, 28-29th November 2018.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
26 06 2020
Historique:
received: 09 01 2020
accepted: 15 01 2020
pubmed: 8 4 2020
medline: 28 4 2021
entrez: 8 4 2020
Statut: ppublish

Résumé

Investment in vaccine product development should be guided by up-to-date and transparent global burden of disease estimates, which are also fundamental to policy recommendation and vaccine introduction decisions. For low- and middle-income countries (LMICs), vaccine prioritization is primarily driven by the number of deaths caused by different pathogens. Enteric diseases are known to be a major cause of death in LMICs. The two main modelling groups providing mortality estimates for enteric diseases are the Institute for Health Metrics and Evaluation (IHME) at the University of Washington, Seattle and the Maternal Child Epidemiology Estimation (MCEE) group, led by Johns Hopkins Bloomberg School of Public Health. Whilst previous global diarrhoea mortality estimates for under five-year-olds from these two groups were closely aligned, more recent estimates for 2016 have diverged, particularly with respect to numbers of deaths attributable to different enteric pathogens. This has impacted prioritization and investment decisions for vaccines in the development pipeline. The mission of the Product Development for Vaccines Advisory Committee (PDVAC) at the World Health Organisation (WHO) is to accelerate product development of vaccines and technologies that are urgently needed and ensure they are appropriately targeted for use in LMICs. At their 2018 meeting, PDVAC recommended the formation of an independent working group of subject matter experts to explore the reasons for the difference between the IHME and MCEE estimates, and to assess the respective strengths and limitations of the estimation approaches adopted, including a review of the data on which the estimates are based. Here, we report on the proceedings and recommendations from a consultation with the working group of experts, the IHME and MCEE modelling groups, and other key stakeholders. We briefly review the methodological approaches of both groups and provide a series of proposals for investigating the drivers for the differences in enteric disease burden estimates.

Identifiants

pubmed: 32253097
pii: S0264-410X(20)30080-3
doi: 10.1016/j.vaccine.2020.01.054
pmc: PMC7306158
pii:
doi:

Substances chimiques

Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

4792-4800

Subventions

Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Références

Front Microbiol. 2017 Jun 29;8:1210
pubmed: 28706515
Electrolyte Blood Press. 2010 Dec;8(2):82-6
pubmed: 21468201
Epidemics. 2016 Dec;17:56-63
pubmed: 27915211
Vaccine. 2017 Dec 14;35(49 Pt A):6783-6789
pubmed: 28765005
Lancet Glob Health. 2019 Mar;7(3):e321-e330
pubmed: 30784633
Lancet Infect Dis. 2017 Sep;17(9):909-948
pubmed: 28579426
Lancet. 2015 Jan 31;385(9966):430-40
pubmed: 25280870
Clin Infect Dis. 2014 Nov 1;59 Suppl 4:S193-206
pubmed: 25305287
Lancet. 2015 Jan 10;385(9963):117-71
pubmed: 25530442
Clin Infect Dis. 2012 Dec;55 Suppl 4:S294-302
pubmed: 23169941
Lancet Glob Health. 2019 May;7(5):e568-e584
pubmed: 31000128
Int J Hyg Environ Health. 2016 Nov;219(8):709-723
pubmed: 27720133
Nat Rev Gastroenterol Hepatol. 2013 Apr;10(4):220-9
pubmed: 23229327
Lancet Glob Health. 2019 Apr;7(4):e472-e481
pubmed: 30797735
Travel Med Infect Dis. 2019 Jan - Feb;27:64-71
pubmed: 29894796
PLoS One. 2014 Apr 09;9(4):e93427
pubmed: 24718483
Vaccine. 2017 Dec 14;35(49 Pt A):6807-6812
pubmed: 28549806
Am J Epidemiol. 2014 Feb 15;179(4):507-12
pubmed: 24305574
Lancet. 2013 Jul 20;382(9888):209-22
pubmed: 23680352
Lancet. 2016 Sep 24;388(10051):1291-301
pubmed: 27673470
Infect Dis (Lond). 2015 Jul;47(7):491-8
pubmed: 25761823
Clin Infect Dis. 2018 Feb 1;66(4):504-511
pubmed: 29029149
Lancet. 2014 Sep 13;384(9947):957-79
pubmed: 24797572
F1000Res. 2018 Feb 15;7:193
pubmed: 29511533

Auteurs

H J Prudden (HJ)

Initiative for Vaccine Research, World Health Organisation, CH-1211 Geneva, Switzerland.

M Hasso-Agopsowicz (M)

Initiative for Vaccine Research, World Health Organisation, CH-1211 Geneva, Switzerland.

R E Black (RE)

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.

C Troeger (C)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA 98121, USA.

R C Reiner (RC)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA 98121, USA.

R F Breiman (RF)

Global Health Institute, Emory University, Atlanta, GA, USA.

M Jit (M)

Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, United Kingdom; Modelling and Economics Unit, National Infections Service, Public Health England, United Kingdom; School of Public Health, University of Hong Kong, Hong Kong.

G Kang (G)

Translational Health Science and Technology Institute, Faridabad, India.

L Lamberti (L)

Bill & Melinda Gates Foundation, Seattle, WA, USA.

C F Lanata (CF)

Instituto de Investigacion Nutricional, Lima, Peru; Department of Pediatrics, School of Medicine, Vanderbilt University, Nashville, TN 37027, USA.

B A Lopman (BA)

Global Health Institute, Emory University, Atlanta, GA, USA.

W Ndifon (W)

African Institute for Mathematical Sciences, Cape Town, South Africa.

V E Pitzer (VE)

Department of Epidemiology and Microbial Diseases, Yale School of Public Health, Yale University, New Haven, CT, USA.

J A Platts-Mills (JA)

Division of Infectious Diseases & International Health, University of Virginia, Charlottesville, VA 22908, USA.

M S Riddle (MS)

Uniformed Services University, Bethesda, MD 120814, USA.

P G Smith (PG)

Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, United Kingdom.

R Hutubessy (R)

Initiative for Vaccine Research, World Health Organisation, CH-1211 Geneva, Switzerland.

B Giersing (B)

Initiative for Vaccine Research, World Health Organisation, CH-1211 Geneva, Switzerland. Electronic address: giersingb@who.int.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH